Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

BACKGROUND: We recently reported improved glycemic control with reduced insulin dose in subjects with type 1 diabetes treated with the sodium glucose co-transporter-2 inhibitor empagliflozin. To further characterize the effects, we analyzed diurnal glycemic patterns by continuous glucose monitoring...

Descripción completa

Detalles Bibliográficos
Autores principales: Perkins, Bruce A., Cherney, David Z. I., Soleymanlou, Nima, Lee, Justin A., Partridge, Helen, Tschirhart, Holly, Zinman, Bernard, Mazze, Roger, Fagan, Nora, Kaspers, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., Johansen, Odd Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636141/
https://www.ncbi.nlm.nih.gov/pubmed/26544192
http://dx.doi.org/10.1371/journal.pone.0141085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636141/
https://www.ncbi.nlm.nih.gov/pubmed/26544192
http://dx.doi.org/10.1371/journal.pone.0141085

Ejemplares similares